About: Argent BioPharma Limited, a clinical-stage biopharmaceutical company, develops nano-engineered therapeutics that reset the balance between the nervous and immune systems in Malta, Slovenia, Australia, and internationally. The company's principal product candidates include CimetrA, which is in phase III clinical trial for the treatment of acute lung injury and ARDS; CannEpil, which is in phase I clinical trial for refractory epilepsy; and CogniCann, which is in phase IIA clinical trial for the symptomatic relief of Dementia and Alzheimer's. It is also involved in the preclinical development of Irnican for the treatment of Glioblastoma Multiforme; and R&D, which focuses on wound treatment. The company has collaborated with SINTEF to enhance antimicrobial therapies for chronic wounds and potential oncologic wound care. The company was formerly known as MGC Pharmaceuticals Limited and changed its name to Argent BioPharma Limited. Argent BioPharma Limited was founded in 2014 and is based in Subiaco, Australia.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Latest price: A$0.04 (-2.50%)
RGTASXArgent Biopharma Ltd
Loading watchlist status…
Argent Biopharma Ltd share price
RGT price activity
Last Price
Change (24hr)
AUD (%)
Volume
-
Volume (4w avg)
-
Previous Close
N/A
Last Trade
RGT price performance
2.63%
5D
-45.83%
1M
-44.29%
YTD
-46.58%
1Y
RGT price fundamentals
N/A
Shares Issued
N/A
Earnings Per Share (EPS)
N/A
Dividends Per Share (DPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
AU-ASX rank
N/ASector Rank
N/ARGT Market Signals